PROLONGED HALOPERIDOL AND REDUCED HALOPERIDOL PLASMA-CONCENTRATIONS AFTER DECANOATE WITHDRAWAL

被引:6
作者
CHANG, WH
LIN, SK
JUANG, DJ
CHEN, LC
YANG, CH
HU, WH
CHIEN, CP
LAM, YWF
JANN, MW
机构
[1] MERCER UNIV,SO SCH PHARM,DEPT PHARM PRACTICE,ATLANTA,GA
[2] MERCER UNIV,SO SCH PHARM,DEPT PHARMACEUT SCI,ATLANTA,GA
[3] TAIPEI MED COLL,TAIPEI,TAIWAN
[4] NATL TAIWAN UNIV,TAIPEI,TAIWAN
[5] UNIV TEXAS,COLL PHARM,DIV CLIN PHARM,AUSTIN,TX 78712
[6] UNIV TEXAS,HLTH SCI CTR,DEPT PHARMACOL,SAN ANTONIO,TX 78284
关键词
HALOPERIDOL; REDUCED HALOPERIDOL; HALOPERIDOL DECANOATE;
D O I
10.1016/0920-9964(93)90007-6
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Haloperidol and reduced haloperidol plasma concentrations were measured in twelve schizophrenic patients upon cessation of haloperidol decanoate (HLD) treatment. Each patient received HLD 100 mg every 4 weeks for five injections. After the fifth injection, HLD was discontinued. Haloperidol and reduced haloperidol plasma concentrations were obtained prior to cessation and at weeks 1, 3, 4, 5, 7, 9, 11, and 13 post-injection. Haloperidol and reduced haloperidol plasma concentrations were assayed by HPLC. Both haloperidol and reduced haloperidol plasma concentrations were detectable 13 weeks post HLD discontinuation. Maximal haloperidol plasma concentrations were observed at one week post cessation and gradually declined. The mean elimination half-life for haloperidol was 27.4 +/- 8.6 days (range 19.0-47.0 days). Reduced haloperidol plasma concentrations declined very slowly. Our results show that both haloperidol and reduced haloperidol plasma concentrations can remain for extended time periods after HLD is discontinued.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 17 条
[1]   HALOPERIDOL DECANOATE IN CHRONIC-SCHIZOPHRENIA - A STUDY OF 12 MONTHS WITH PLASMA-LEVELS [J].
ALTAMURA, CA ;
COLACURCIO, F ;
MAURI, MC ;
MORO, AR ;
DENOVELLIS, F .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1990, 14 (01) :25-35
[2]  
CHANG WH, 1989, BIOL PSYCHIAT, V26, P239
[3]  
CHANG WH, 1989, J CLIN PHARMACOL, V28, P841
[4]  
EKLUND K, 1991, CLIN NEUROPHARMACOL, V14, pS7
[5]   PHARMACOKINETICS OF HALOPERIDOL [J].
FROEMMING, JS ;
LAM, YWF ;
JANN, MW ;
DAVIS, CM .
CLINICAL PHARMACOKINETICS, 1989, 17 (06) :396-423
[6]  
GITLIN MJ, 1988, J CLIN PSYCHOPHARM, V8, P53
[7]   CLINICAL PHARMACOKINETICS OF THE DEPOT ANTIPSYCHOTICS [J].
JANN, MW ;
ERESHEFSKY, L ;
SAKLAD, SR .
CLINICAL PHARMACOKINETICS, 1985, 10 (04) :315-333
[8]   REVERSIBLE METABOLISM OF HALOPERIDOL AND REDUCED HALOPERIDOL IN CHINESE SCHIZOPHRENIC-PATIENTS [J].
JANN, MW ;
LAM, YWF ;
CHANG, WH .
PSYCHOPHARMACOLOGY, 1990, 101 (01) :107-111
[9]  
KO GN, 1989, J CLIN PSYCHOPHARM, V9, P186
[10]   HALOPERIDOL DECANOATE V FLUPHENAZINE DECANOATE AS MAINTENANCE THERAPY IN CHRONIC-SCHIZOPHRENIC INPATIENTS [J].
MCKANE, JP ;
ROBINSON, ADT ;
WILES, DH ;
MCCREADIE, RG ;
STIRLING, GS .
BRITISH JOURNAL OF PSYCHIATRY, 1987, 151 :333-336